Geniposide-Loaded Biomimetic Nanoparticles Modulate HMOX1 To Alleviate Neuroinflammation in Depression

Area of Science:

• Neuroscience
• Pharmacology
• Biotechnology

Background:

• Depression is linked to neuroinflammation and altered microglial function.
• Heme oxygenase-1 (HMOX1) is crucial in regulating oxidative stress and neuroinflammation.

Purpose of the Study:

• To investigate geniposide-loaded biomimetic nanoparticles (CSPG@CM) for targeted microglial modulation in depression.
• To assess the therapeutic potential of CSPG@CM in preclinical models of depression.

Main Methods:

• Utilized systems pharmacology, computational biology, cell-based assays, and animal models.
• Developed geniposide-loaded biomimetic nanoparticles (CSPG@CM) for enhanced drug delivery.
• Evaluated CSPG@CM efficacy in a chronic unpredictable mild stress (CUMS) mouse model.

Main Results:

• CSPG@CM nanoparticles improved geniposide bioavailability and targeted microglia effectively.
• Treatment upregulated HMOX1, reduced pro-inflammatory cytokines, and enhanced neuronal survival.
• CSPG@CM alleviated depressive behaviors, reduced neuroinflammation, and restored homeostasis in CUMS mice.

Conclusions:

• Geniposide-loaded nanoparticles offer a promising strategy for precise modulation of neuroinflammatory pathways in depression.
• This nanotherapeutic approach demonstrates superior efficacy compared to free geniposide.
• CSPG@CM nanoparticles represent a potential innovative therapy for antidepressant treatment.